Anti-TNF agents have been the cornerstone of IBD therapy in recent decades and, mainly after the approval of biosimilars, they have been commonly used as the first targeted therapy in most patients (mainly due to reimbursement policies). The gene discussed is TNF; the disease is inflammatory bowel disease.